neuroendocrine carcinoma

https://pubmed.ncbi.nlm.nih.gov/37914572/

Gastroenteropancreatic neuroendocrine carcinoma tumor spheroid drug screen reveals vulnerability to...

Both NEC913 and NEC1452 gastroenteropancreatic neuroendocrine carcinoma spheroid lines are useful preclinical models for drug testing. Our library screen...

neuroendocrine carcinoma drug screen tumor spheroid reveals

https://www.mskcc.org/cancer-care/types/gastrointestinal-neuroendocrine/large-cell-small-cell-gastrointestinal-neuroendocrine-carcinoma

Large Cell & Small Cell Gastrointestinal Neuroendocrine Carcinoma | Memorial Sloan Kettering Cancer...

Gastrointestinal neuroendocrine carcinomas are rare tumors, but Memorial Sloan Kettering experts have experience treating both large cell neuroendocrine...

memorial sloan kettering large cell neuroendocrine carcinoma small gastrointestinal

https://pubmed.ncbi.nlm.nih.gov/2841895/

Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized...

Twenty-nine patients with poorly differentiated neuroendocrine tumors of unknown primary site were seen at Vanderbilt Medical Center between May 1977 and...

neuroendocrine carcinoma poorly differentiated unknown primary

https://www.mdpi.com/2077-0383/11/5/1461

Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges

Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare and highly aggressive type of lung cancer, with a complex biology that shares similarities...

large cell neuroendocrine carcinoma lung current understanding

https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-neuroendocrine-carcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-349437&utm_campaign=recommended-articles-pi

Durvalumab by AstraZeneca for Neuroendocrine Carcinoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

neuroendocrine carcinoma durvalumab astrazeneca likelihood approval

https://scirp.org/journal/paperinformation?paperid=65671

Multiple Spinal Intradural-Intramedullary Involvement by Metastatic Carcinoma with Neuroendocrine...

Rare case of intramedullary spinal metastasis with neuroendocrine differentiation. Learn about its unusual presentation, MRI findings, and the importance of...

metastatic carcinoma multiple spinal intramedullary involvement

https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-neuroendocrine-carcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-279183&utm_campaign=recommended-articles-pi

Irinotecan hydrochloride by Ipsen for Neuroendocrine Carcinoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Carcinoma.

irinotecan hydrochloride neuroendocrine carcinoma ipsen likelihood approval

https://pubmed.ncbi.nlm.nih.gov/3337533/

Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in...

Squamous cell carcinoma and neuroendocrine (Merkel cell) carcinoma are cutaneous neoplasms that have only occasionally been reported to coexist. Squamous cell...

merkel cell carcinoma development neuroendocrine mixed squamous

Robuta